LeMaitre Vascular (LMAT) vs Pulse Biosciences (PLSE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pulse Biosciences (PLSE) has outperformed LeMaitre Vascular (LMAT) over the past year, gaining 150.7% versus a loss of 9.5%. Over five years, PLSE leads with a +130.9% price change compared with +48.6% for LMAT. Pulse Biosciences is the larger company by market cap ($3.84 billion vs $1.85 billion), about 2.1 times the size.
LeMaitre Vascular pays a dividend yielding 1.12%, while Pulse Biosciences does not currently pay one. LeMaitre Vascular converts more of its revenue into profit, with a net margin of 23.1% versus -20794.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LMAT | PLSE |
|---|---|---|
| Share price | $80.69 | $53.81 |
| Market cap | $1.85B | $3.84B |
| 1-day change | +1.32% | +7.66% |
| YTD return | -1.80% | +264.02% |
| 1-year return | -9.54% | +150.65% |
| 5-year return | +48.64% | +130.85% |
| P/E ratio (TTM) | 28.31 | — |
| Forward P/E | 25.38 | — |
| EPS (TTM) | $2.85 | $-1.18 |
| Dividend yield | 1.12% | 0.00% |
| Annual dividend | $0.90 | $0.00 |
| Revenue (latest FY) | $249.60M | $350.00K |
| Revenue growth (YoY) | +13.53% | — |
| Net income (latest FY) | $57.73M | $-72.78M |
| Gross margin | 71.53% | -54.00% |
| Operating margin | 27.21% | -21982.57% |
| Net margin | 23.13% | -20794.57% |
| 52-week high | $118.01 | $58.90 |
| 52-week low | $78.22 | $12.56 |
| Distance from 52-week high | -31.62% | -8.64% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +32.61% | +5.00% |
| Average volume | 330.14K | 502.81K |
| Shares outstanding | 22.87M | 71.32M |
| Employees | 646 | 116 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Pulse Biosciences is about 2.1 times larger than LeMaitre Vascular by market value ($3.84B vs $1.85B).
- PLSE has outperformed LMAT by 160.2 percentage points over the past year.
- LeMaitre Vascular offers a meaningfully higher dividend yield (1.12% vs 0.00%).
- LeMaitre Vascular is more profitable, keeping 23.1 cents of every revenue dollar as net income versus -20794.6 cents for Pulse Biosciences.
About LeMaitre Vascular
LMAT stock →LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific.
Health Care · Medical/Dental Instruments · 646 employees
About Pulse Biosciences
PLSE stock →Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
Health Care · Medical/Dental Instruments · 116 employees
LMAT vs PLSE FAQ
Which is bigger, LeMaitre Vascular or Pulse Biosciences?
Pulse Biosciences (PLSE) is larger, with a market capitalization of $3.84B compared with $1.85B for LeMaitre Vascular (LMAT).
Which stock has performed better over the past year, LMAT or PLSE?
PLSE returned +150.65% over the past 12 months, compared with -9.54% for LMAT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, LeMaitre Vascular or Pulse Biosciences?
LeMaitre Vascular pays a dividend yielding 1.12%, while Pulse Biosciences does not currently pay a regular dividend.
Are LeMaitre Vascular and Pulse Biosciences in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.